Expression of vasopressin mRNA in the hypothalamus of individuals with a diagnosis of schizophrenia by Busch, Johannes R et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Expression of vasopressin mRNA in the hypothalamus of individuals with a diagnosis
of schizophrenia
Busch, Johannes R; Jacobsen, Christina; Lynnerup, Niels; Banner, Jytte; Møller, Morten
Published in:
Brain and Behavior
DOI:
10.1002/brb3.1355
Publication date:
2019
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Busch, J. R., Jacobsen, C., Lynnerup, N., Banner, J., & Møller, M. (2019). Expression of vasopressin mRNA in
the hypothalamus of individuals with a diagnosis of schizophrenia. Brain and Behavior, 9(9), [e01355].
https://doi.org/10.1002/brb3.1355
Download date: 03. Feb. 2020
Brain and Behavior. 2019;9:e01355.	 	 	 | 	1 of 8
https://doi.org/10.1002/brb3.1355
wileyonlinelibrary.com/journal/brb3
1  | SIGNIFIC ANT OUTCOMES
The expression of mRNA encoding vasopressin in the magnocellular 
hypothalamic nuclei is decreased in individuals with the diagnosis of 
schizophrenia.
2  | LIMITATIONS
The tissue preservation of the brains in a forensic autopsy material 
varies.
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Abstract
Objective: This study investigates the expression of mRNA encoding vasopressin in 
the hypothalamus of autopsy brains of individuals diagnosed with schizophrenia.
Methods: Ten brains of individuals with schizophrenia and 10 brains from individu-
als without any disease were examined during autopsy. The hypothalamic block was 
dissected and immersion fixed in paraformaldehyde, sucrose substituted, frozen, and 
cut	into	20-µm-thick	coronal	cryostat	sections.	The	sections	were	hybridized	with	an	
S-35-labeled	DNA	antisense	oligo	probe	and	after	washing	covered	by	an	X-ray	film.	
The hybridization signals on the films were transferred to a computer and densito-
metrically quantified.
Results: The densitometry signals showed a statistically significant lower mRNA ex-
pression (53% decrease; p = 0.014) in the paraventricular nucleus of the individuals 
with schizophrenia compared to the controls. In the supraoptic nucleus, the decrease 
in the group with schizophrenia was 39% compared to the controls, but this decrease 
was not statistically significant (p = 0.194).
Conclusions: Our results show a low expression of mRNA encoding vasopressin in 
the paraventricular nucleus of the individuals with schizophrenia. We suggest that 
vasopressin is not directly involved in the pathogenesis of schizophrenia, but might 
influence schizophrenic symptoms via vasopressin receptors located in the social be-
havioral neural network in the forebrain.
K E Y W O R D S
mRNA, paraventricular, schizophrenia, vasopressin
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3  | INTRODUC TION
Schizophrenia is a major psychiatric disorder with an unknown causa-
tive pathophysiology (Birnbaum & Weinberger, 2017). Stress could be 
a factor in the pathophysiology of the disease, and that might involve 
the endocrine hypothalamic–pituitary–adrenal axis. Thus, stress dis-
orders	have	been	 found	often	 to	 co-occur	with	 schizophrenia	 (Seow	
et al., 2016; Young et al., 2013) although measurements of the stress 
hormone, cortisol, in plasma and saliva in schizophrenia patients have 
shown both high, normal, and low levels compared to controls (Bradley 
& Dinan, 2010). However, several studies measuring the hypothalamic–
pituitary–adrenal axis response to psychological stress in schizophrenic 
patients have demonstrated a blunted adrenocorticotropic hormone 
(ACTH)	and	cortisol	response	to	stress	(Brenner	et	al.,	2009;	Goldman,	
Gnerlich,	&	Hussain,	2007;	Jansen	et	al.,	1998)	 indicating	an	 involve-
ment of the hypothalamic–pituitary–adrenal axis in the pathophysiol-
ogy of schizophrenia.
The nona peptide, vasopressin, is a part of the hypothalamic–
pituitary–adrenal axis. This hormone is located in magnocellular 
neurons in the human hypothalamic paraventricular nucleus of the 
hypothalamus	(Møller	et	al.,	2018;	Saper,	2012)	in	which	parvocel-
lular	 neurons,	 containing	 corticotropin-releasing	 hormone	 (CRH),	
also are located. Although the main function of vasopressin, also 
called the antidiuretic hormone (ADH), is the regulation of water 
re-absorption	in	the	kidney,	via	projections	of	axons	to	the	posterior	
pituitary lobe and release of the hormone to the vascular system, 
vasopressin is also involved in regulation of cortisol from the supra-
renal	 glands	 (Aguilera	&	Rabadan-Diehl,	 2000).	 Thus,	 vasopressin	
released via the portal capillaries of the median eminence to the 
anterior lobe of the pituitary stimulates the pituitary ACTH secre-
tion by potentiating the stimulatory effects of CRH on the pituitary 
ACTH	secreting	cells	(Aguilera	&	Rabadan-Diehl,	2000;	Naughton,	
Dinan, & Scott, 2014).
In addition to the involvement in water regulation and stress, va-
sopressin modulates social interactions (Donaldson & Young, 2008), 
and intranasal administration of the vasopressin analogue desmo-
pressin has shown a positive effect on negative schizophrenic symp-
toms (Brambilla et al., 1989; Hosseini et al., 2014).
Several studies have shown alterations in vasopressin levels in 
plasma and cerebrospinal fluid in schizophrenic patients (Bradley & 
Dinan, 2010; Jobst et al., 2014). Although some earlier studies have 
shown elevated level of vasopressin, most studies have shown a 
lower level in schizophrenia patients compared to human controls 
(Frederiksen,	Ekman,	Gottfries,	Widerlöv,	&	Jonsson,	1991;	Rubin	et	
al., 2013, 2014).
Modern	molecular	biological	methods	have	made	it	possible	to	
determine the amount of mRNA encoding for vasopressin in the 
hypothalamic neurons of the hypothalamus. We have in this study, 
by use of quantitative radioactive in situ hybridization, compared 
the intensity of the mRNA signal in sections of the hypothalamus 
from brains removed during autopsies of individuals with a diag-
nosis of schizophrenia to the signal intensity in a series of control 
brains. Our results demonstrate a lower mRNA expression level in 
the brains of the schizophrenic patients compared to the levels in 
the controls.
3.1 | Aims of the study
1. In a series of autopsy brains to determine the expression lev-
els of mRNA encoding vasopressin in the hypothalamus of 
individuals with the diagnosis of schizophrenia.
2. To compare the expression in the brains of schizophrenic individ-
uals with the expression in a control series.
Our hypothesis is that vasopressin is not directly involved in the 
pathogenesis of schizophrenia, but might influence schizophrenic 
symptoms.
4  | MATERIAL S AND METHODS
4.1 | Removal of specimens and fixation
Brains used in this study were examined during autopsies performed 
at	the	Department	of	Forensic	Medicine,	University	of	Copenhagen,	
as	a	part	of	the	Danish	National	SURVIVE	study	http://retsm	edicin.
ku.dk/engli sh/resea rch/survi vepro jects/ . Ten of the brains were 
from individuals with a diagnosis of schizophrenia and 10 additional 
brains were from persons without any brain pathology or disease 
and served as controls (for detailed subject data, see Table 1). Family 
members were asked for permission to use the tissues for scientific 
investigations and publishing of data. The study conforms to recog-
nized	standards,	for	example:	Declaration	of	Helsinki	(WMA	General	
Assembly,	Seoul,	Korea,	October	2008).	The	SURVIVE	study	was	ap-
proved by the Danish National Committee on Research Ethics (ref-
erence number: 1305373) and the Danish Data Protection Agency 
(reference	number:	SUND-2016-16).
During examination of the brain, a tissue block containing the hy-
pothalamus was dissected from the ventral part of the forebrain. The 
rostral boundary was a coronal section 0.75 cm rostral to the optic 
chiasm, and the caudal boundary was just behind the mammillary 
bodies. Laterally, two sagittal sections were made through the optic 
tracts 2 cm lateral to the midline (third ventricle). The hypothalamus 
was finally isolated from the dorsal part of the diencephalon with a 
horizontal cut just below the thalamic nuclear complex above the 
hypothalamic sulcus.
The tissue blocks were fixed in 4% formalin for 2–4 months and 
after fixation cryoprotected in 25% sucrose in distilled water for 
7 days. The tissues blocks of the hypothalamus were then frozen in 
crushed	carbon	dioxide	and	stored	at	−80°C.	Twenty-micrometer-
thick serial coronal sections through the supraoptic area were cut in 
a Leitz cryostat and mounted on Super Frost®	glass	slides	(Menzel).	
Every 10th section was Nissl counter stained. Four sections of the 
coronal series were selected for in situ hybridization. The first ros-
tral section was cut through the middle of the optic chiasm, where 
the supraoptic nucleus is large and exhibiting a triangular shape. The 
next three sections used for in situ hybridizations were located 100, 
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200,	 and	 300	µm	 caudal	 to	 first	 rostral	 section.	 The	 sections	 se-
lected	for	in	situ	hybridizations	were	stored	at	−80°C.
4.2 | Radiochemical in situ hybridization for 
histological detection of vasopressin transcripts
Tissue sections were thawed and washed 2 × 1 min in PBS. This 
was followed by acetylation in 0.25% acetic anhydride (diluted 
in 0.1 m triethanolamine and 0.9% NaCl) for 10 min. The sections 
were then dehydrated in a graded series of ethanols and delipi-
dated in 100% chloroform, followed by partial rehydration in 95% 
ethanol.	A	48-mer	 antisense	DNA	probe	 corresponding	 to	bases	
1960–2007	 of	 human	 vasopressin	 mRNA	 (XM_011529267;	 5′-
gcaaggccccggccggcccgtccagctgcgtggcgttgctccggtcgc-3′)	 was	 di-
luted	in	DEPC-treated	water	to	a	concentration	of	5	pmol/µl.	Five	
microliters of the probe was then labeled with [35S]dATP (code 
nr.	 NEG034H250UC;	 Perkin	 Elmer)	 by	 use	 of	 terminal	 trans-
ferase (code nr. 3333566001; Roche) to a specific activity of 
1 × 1018 dpm/mol. The labeled probe was diluted in a hybridiza-
tion	buffer	(5	µl	labeled	probe/ml	hybridization	buffer)	consisting	
of 50% (v/v) formamide, 4 × SSC (SSC: 150 mm NaCl, 15 mm sodium 
citrate, pH 7.0), 1 × Denhardt solution (0.02% bovine serum albu-
min, 0.02% polyvinylpyrrolidone, 0.02% ficoll), 10% (w/v) dextran 
sulfate, 10 mm dithiothreitol, 0.5 mg/ml salmon sperm DNA, and 
0.5 mg/ml yeast tRNA. The sections were hybridized in a humid 
chamber	 overnight	 at	 37°C.	 After	 hybridization,	 the	 slides	 were	
washed	in	1	×	SSC	for	4	×	15	min	at	55°C,	2	×	30	min	at	room	tem-
perature and rinsed in deionized water.
The	sections	were	dried	and	exposed	to	an	X-ray	film	for	19	days.	
After development of the films, the images of the sections were 
transferred to a computer and quantified by use of the software 
ScionImage (Wayne Rasband, National Institutes of Health). Optical 
densities were converted to dpm/mg tissue by using simultaneously 
exposed 14C-standards	 calibrated	 by	 comparison	 with	 35S-tissue	
paste standards. Signals from the supraoptic and paraventricular nu-
clei on both sides of the hypothalamus were obtained.
4.3 | Controls
In situ hybridizations were done on parallel sections of the same hy-
pothalamic blocs with sense and antisense probes against vasopres-
sin	and	corticotropin-releasing	hormone	(CRH).
4.4 | Statistical data analysis
The	densities	of	the	vasopressin	expression	signals	on	the	X-ray	films	
in the paraventricular and the supraoptic nuclei were analyzed by 
use	of	GraphPad	Prism	7.0.	The	signals	from	the	individuals	with	a	
schizophrenia diagnosis and the control brains were compared in the 
paraventricular nuclei and also in the supraoptic nuclei by use of the 
unpaired Student's t test. A p-value	below	0.05	was	considered	sta-
tistical significant.
TA B L E  1   Clinicopathological data of the cases studied
Age
Minimal postmortem 
interval (days)
Maximal postmortem 
interval (days) Gender
Schizophrenia 
diagnosis Cause of death
43 6,5 7,5 Male No Poisoning
56 6,1 7,3 Female No Hypovolemia
58 4,6 4,9 Male No Heart failure
48 0,9 1,0 Female No Asphyxia
30 4,2 11,0 Male No Ketoacidosis
72 4,2 6,6 Female No Pulmon.embolism
21 5,3 6,0 Male No Poisoning
65 3,4 4,3 Female No Asphyxia
60 5,4 6,1 Male No Poisoning
71 2,7 2,8 Male No Poisoning
58 2,4 3,2 Female Yes Poisoning
58 6,1 6,2 Female Yes Asphyxia
41 5,6 6,1 Male Yes Poisoning
49 7,5 8,1 Male Yes Undetermined
31 11,1 11,1 Female Yes Asphyxia
45 17,1 17,1 Male Yes Poisoning
59 1,4 2,0 Female Yes Poisoning
45 3,5 3,6 Male Yes Heart failure
42 4,1 4,1 Male Yes Pulmon.embolism
67 4,5 5,1 Female Yes Heart failure
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5  | RESULTS
5.1 | Morphology of the paraventricular and 
supraoptic nuclei in the supraoptic region
In coronal sections, the bilateral magnocellular paraventricular nu-
clei are located just lateral to the third ventricle exhibiting an ovoid 
shape along the ventricle (Figure 1a,b). The large supraoptic nuclei 
are located ventrally in the hypothalamus just above the inferior sur-
face. At the level of the optic chiasm, the nuclei exhibit a triangular 
shape just lateral to the chiasm (Figure 1a,b), but possess a long and 
thin tail region stretching along the optic tracts.
5.2 | Densitometry of the vasopressin expression 
signals in the paraventricular and supraoptic nuclei 
in the supraoptic region
Both the supraoptic and paraventricular nuclei showed strong 
radioactive	 signals	 on	 the	 developed	 X-ray	 films,	 indicating	 a	
high expression of vasopressin in these nuclei (Figure 2a,b). The 
signals were located above the magnocellular perikarya of the 
paraventricular and supraoptic nuclei. The intensity of the signals 
was lower in the sections of the individuals with the diagnosis of 
schizophrenia compared to the sections from the controls. This was 
F I G U R E  1   Nissl counterstaining of 
the sections used for in situ hybridization 
for mRNA encoding vasopressin, the 
expression signals of which are shown in 
Figure 2. (a) Section from a control brain. 
(b) Section from the brain of an individual 
with the diagnosis of schizophrenia. 3rd 
ventr, third ventricle. Bars = 1 mm
(a) (b)
F I G U R E  2  X-ray	images	of	coronal	
sections through the supraoptic area 
of the hypothalamus hybridized with 
an antisense oligo probe against mRNA 
encoding vasopressin. On the left (a) a 
section from a control brain and to the 
right (b) a section from an individual 
with a diagnosis of schizophrenia. 
Expression signals are seen above the 
nerve cell bodies in the supraoptic and 
paraventricular nuclei in both sections, 
but the intensity is lower in the section 
from the individual with the diagnosis of 
schizophrenia. 3rd ventr, third ventricle. 
Bars = 1 mm
(a) (b)
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confirmed in the densitometry measurements of the signals on the 
films showing a statistical significant lower signal (53% decrease) in 
the paraventricular nucleus of the schizophrenic patients compared 
to the controls (Figure 3). In the supraoptic nucleus, the decrease in 
the schizophrenic patients was 39% compared to the controls, but 
this decrease was not statistically significant (Figure 3).
6  | DISCUSSION
Many	 reports	 regarding	 vasopressin	 and	 schizophrenia	 have	 been	
published but a clear picture of how this hormone is involved in the 
disease has not been obtained, and the results obtained are still 
conflicting.
Thus, changes in the amount of vasopressin in the brain of 
schizophrenic patients were first reported in investigations 30 years 
ago, in which a decrease in vasopressin in the temporal cortex was 
observed, but a reduction in the hypothalamus was not detected 
(Frederiksen et al., 1991).
Studies of the plasma levels of vasopressin in schizophrenic pa-
tients	 have	 been	 giving	 conflicting	 results.	Most	 studies	 have	 re-
ported a decrease in vasopressin levels of schizophrenic patients 
compared	 to	 controls	 (Goldman	 et	 al.,	 2007;	 Jobst	 et	 al.,	 2014;	
Linkowski,	 Geenan,	 Kerkhofs,	Mendlewicz,	 &	 Legros,	 1984;	 Ryan,	
Sharifi, Condren, & Thakore, 2004). However, in a recent study, an 
increase in plasma concentration of vasopressin in schizophrenic pa-
tients	compared	to	controls	was	reported	(Guzel	et	al.,	2018).	Also,	
in a recent study by Aydin and coworkers no difference in plasma 
vasopressin	in	schizophrenic	patients	was	detected	(Aydın,	Lysaker,	
Balıkçı,	 Ünal-Aydın,	 &	 Esen-Danacı,	 2018).	 The	 time	 of	 day	when	
the blood samples were obtained was rarely given in above quoted 
studies. However, because neither the CSF nor plasma levels show 
a significant circadian rhythm in adult humans (Barreca et al., 1988; 
Mahler	et	al.,	2013),	the	difference	in	plasma	levels	obtained	in	these	
studies cannot be due to variations in circadian time between study 
groups. We have in this study not been able to obtain information 
about medication, including neuroleptics, taken by the controls 
and schizophrenic patients. This would have been of interest due 
to influence of dopamine agonists and antagonists on vasopressin 
secretion (Locatelli, Bresciani, Tamiazzo, & Torsello, 2010). Forensic 
toxicology showed the presence of antipsychotics in two in the 
control group and four in the schizophrenic group. Treatment with 
neuroleptics, which are dopamine antagonist, should have resulted 
in a decreased vasopressin release and higher vasopressin immuno-
reactivity in the neurons of the paraventricular nucleus. However, 
the change in the expression of mRNA encoding vasopressin after 
neuroleptics is uncertain.
The decrease in hypothalamic expression of mRNA encoding 
vasopressin in individuals with a diagnosis of schizophrenia found 
in this study is in accord with the majority of earlier studies. Thus, 
already	 investigations	made	 by	 Gerber,	 who	 applied	 Gomori's	 tri-
chrome staining to hypothalamic sections, observed a reduced 
cellular content of neurosecretory granules in neurons of neurolep-
tic-treated	individuals	with	schizophrenia	(Gerber,	1965).	Later	using	
antibodies against neurophysin I and neurophysin II, the carrier pro-
teins for vasopressin (neurophysin II) and oxytocin (neurophysin I), a 
reduction of neurophysin immunoreactive neurons in the paraven-
tricular nucleus was observed in schizophrenic patients compared to 
controls (Bernstein, Dobrowolny, Bogerts, Keilhoff, & Steiner, 2018; 
Mai,	Berger,	&	Sofroniew,	1993).
Our observation of a decreased expression of mRNA encoding 
vasopressin in only the paraventricular nucleus and not in the su-
praoptic nucleus is also in accord with most previous studies. Thus, 
in	 the	 above	quoted	 study	by	Mai	 et	 al.	 (1993),	 these	 authors	did	
not find a reduction in neurophysin staining in the supraoptic nu-
cleus of the schizophrenic patients compared to controls. Further, in 
a combined immunohistochemical and in situ hybridization study of 
vasopressin in the supraoptic nucleus, it was not possible to detect 
any difference in vasopressin expression and vasopressin mRNA 
expression in this nucleus in schizophrenic patients compared to 
controls	 (Panayotacopoulou,	Malidelis,	 Heerikhuize,	 Unmehopa,	 &	
Swaab, 2005).
An important question related to this study is the stability of 
mRNA encoding vasopressin in the human autopsy brains, used in 
our investigation, as a function of postmortem time. The effect of 
F I G U R E  3   Bar graph of the densitometry determinations of 
the vasopressin signals in the hypothalamic sections of control 
person and a person with the diagnosis of schizophrenia. Ordinate 
shows disintegrations per minutes per mg tissue. The columns 
on the abscissa show the signal means of the sections from the 
paraventricular nuclei of control persons (Control paraventr) and 
signal means of the sections from individuals with the diagnosis of 
schizophrenia (Schiz paraventr); further, signal means of supraoptic 
control sections (Control supraoptic) and supraoptic sections from 
individuals with the diagnosis of schizophrenia (Schiz supraoptic). 
n = 10. p-values	obtained	by	use	of	the	unpaired	Student's	t test are 
shown above the bars. The line above average is the standard error 
of mean (SEM)
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the postmortem interval and preservation of mRNA in autopsy ma-
terials has been investigated in several studies (Birdsill, Walker, Lue, 
Sue, & Beach, 2011; Durrenberger et al., 2010; Stan et al., 2006; 
Trabzuni et al., 2011; White et al., 2018). In several of these studies, 
it has been difficult to verify a direct relationship between the post-
mortem time of the brain tissue and mRNA degradation. However, in 
the paper by Birdsill et al. (2011) it is shown that RNA degrades pro-
gressively	with	increasing	postmortem	time	but	with	high	between-
subject variability. This might be due to variable agonal conditions 
and especially the temperature environment (White et al., 2018).
In our immunohistochemical investigations of the accessory 
magnocellular neurosecretory system of the human hypothalamus 
(Møller	et	al.,	2018),	we	found	no	correlation	between	the	postmor-
tem time and the immunoreactivity in our sections. An explanation 
for that several of our autopsy brains with long postmortem time 
has preserved protein, and mRNA might be due to the fact that the 
dead bodies in our study were kept cold in the morgue during most 
of the postmortem time, and after removal of the brains, these were 
immediate fixed by immersion in cold formalin.
It has not been possible in our histological study to do reverse 
transcription-polymerase	 chain	 reactions	 (qRT-PCR)	 on	 the	 same	
tissue. However, we have performed a linear regression analysis of 
the expression signals in the paraventricular nucleus of the control 
brains as a function of postmortem time (Figure 4). Although the re-
gression line of Figure 4 shows a decline of mRNA expression as a 
function of postmortem days, the slope deviation is not significant 
from zero (p = 0.115).
Regarding a possible physiological influence of vasopressin on 
brain function, it must be kept in mind that effector molecule is the 
peptide and not the mRNAs encoding the peptides. This raises the 
question of whether mRNA expression is correlated with the pep-
tide	or	protein	expression.	Recent	advances	in	next-generation	DNA	
sequencing and proteomics have provided an ability to study mRNA 
and protein abundances in cells. By use of these techniques in mam-
malian cells, 30%–40% of the variance in protein abundance can be 
explained	by	mRNA	abundance	(Vogel	&	Marcotte,	2012).	This	prob-
lem has also been investigated in human postmortem hypothalamus. 
Thus, a combined immunohistochemical and in situ hybridization 
study showed that the number of cell bodies immunoreactive to ty-
rosine	hydroxylase,	 the	 rate-limiting	enzyme	 in	 the	 catecholamine	
synthesis, and mRNA encoding tyrosine hydroxylase was well cor-
related (Panayotacopoulou et al., 2005). We have in our material of 
the brains of deceased with schizophrenia investigated the expres-
sion of proteins by use of antibodies against both vasopressin and 
neurophysin. Both hormones are present in neurons in the paraven-
tricular and supraoptic nuclei. However, due to the variations in the 
immunohistochemical staining in our material, we did not perform 
a quantification of these expressions. This indicates that the immu-
nohistochemical technique is less sensitive than the radioactive in 
situ hybridization (Kim et al., 2009), also in postmortem brain tissue.
Schizophrenia is a complex neurobiological disorder in which ge-
netic, developmental, and environmental factors have been identi-
fied to play a role (Birnbaum & Weinberger, 2017; Keller, 2018). The 
final pathophysiology involves a dysregulation of dopaminergic, glu-
tamatergic,	 GABAergic,	 and	 cholinergic	 neurotransmitter	 systems	
and their interactions (Siever & Davis, 2004).
How the low vasopressin expression in the paraventricular nu-
cleus in schizophrenic patients is involved in the disease is not clear. 
The low expression of mRNA encoding vasopressin in the classical 
magnocellular hypothalamic nuclei indicates that stress involving 
these nuclei is not an important factor in the disease. We have also 
tried	in	situ	hybridization	for	mRNA	encoding	for	corticotropin-re-
leasing hormone, but have not obtained satisfactory signals for this 
mRNA.
Although vasopressin might not be directly a factor in the patho-
genesis of the schizophrenia, the hormone might contribute to 
the symptomology of the disease. Thus, vasopressin in humans is 
capable	of	influencing	a	wide	variety	of	behavioral	traits	(Bachner-
Melman	&	Ebstein,	2014;	Landgraf,	Wotjak,	Neumann,	&	Engelmann,	
1998) for example, traits associated with arousal, vigilance, and de-
fensive behaviors, symptoms often seen in schizophrenia (Reser, 
2007). This possible function of vasopressin in humans is supported 
by numerous animal studies showing the involvement of vasopressin 
in social recognition, communication, and aggression (Albers, 2012). 
There is considerable evidence that many of the effects of vasopres-
sin on social behavior are mediated by the vasopressin 1a and 1b 
receptor subtypes (Stevenson & Caldwell, 2012). These receptors 
are	 extensively	 expressed	 throughout	 the	 so-called	 social	 behav-
ior neural network in the forebrain, a network composed of neu-
ral groups located in the lateral septum, amygdala, and the preoptic 
area in rodent and primate species (Newman, 1999). These areas also 
show high vasopressin binding in the human brain (Loup, Tribollet, 
Dubois-Dauphin,	&	Dreifuss,	1999).
Finally, vasopressin and vasopressin analogs applied intranasal 
to schizophrenic patients resulted in an improvement of both the 
F I G U R E  4   Linear regression analysis of postmortem days versus 
expression of mRNA encoding vasopressin in the paraventricular 
nucleus of hypothalamus of control brains. The expression signal 
shown on the ordinate is disintegrations per minute per mg tissue 
obtained in sections of the control brains. R square = 0.08095, 
p = 0.1145
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patient's	 memory	 functions	 (Geng	 et	 al.,	 2017)	 and	 the	 negative	
symptoms (Jobst et al., 2014).
Summarizing, this paper shows a reduced expression of mRNA 
encoding vasopressin in the paraventricular nucleus, in brains of indi-
viduals with the diagnosis schizophrenia, compared to control brains. 
No change was seen in the supraoptic nucleus of the hypothalamus. 
Vasopressin	is	probably	not	directly	involved	in	the	pathogenesis	of	
schizophrenia, but might influence schizophrenic symptoms.
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